Maintenance therapy using PARP inhibitors is increasingly being recognized as a paradigm shift in the treatment of patients with advanced ovarian cancer, particularly those harbouring BRCA1/2 mutations or HRD. The gene discussed is BRCA1; the disease is ovarian cancer.